Skip to main content

Table 2 Different treatment combination and median duration of response

From: Apatinib for advanced sarcoma: results from multiple institutions’ off-label use in China

Target therapy

Patient number (N)

Best responsea

Median (average) DR (months)

Apatinib alone

44 (78.6%)

PR

3.8 (5.4)

Apatinib+everolimus

7 (12.5%)

PR

8.5 (7.3)

Apatinib+GTb

5 (8.9%)

PR

8.5 (7.3)

  1. aPR partial response, SD stable disease according to RECIST 1.1
  2. bGT chemo-protocol combined with gemcitabine 1000 mg/m2 d1,8 and docetaxel 75 mg/m2 d8 once every 21 days